Assanasen Paraya, Naclerio Robert M
University of Chicago, Chicago, Illinois, USA.
Clin Allergy Immunol. 2002;17:101-39.
Data from in vitro, in vivo, and ex vivo studies suggest that second-generation antihistamines have a number of antiallergic, anti-inflammatory properties that appear to be independent of their H1-blockade activity. First-generation antihistamines also have antiallergic, anti-inflammatory properties, as suggested by the studies with azatadine, chlorpheniramine, mepyramine, and promethazine; most other first-generation antihistamines have not been studied for these properties. In vitro studies have shown that H1-antihistamines reduce the release of proinflammatory mediators from mast cells and basophils, the chemotaxis and activation of inflammatory cells (especially eosinophils), and the expression of adhesion molecules induced by immunological and nonimmunological stimuli in epithelial cell lines. Nasal allergen challenge models have similarly demonstrated that H1-antihistamines inhibit mediator release from mast cells and basophils, and that they decrease inflammatory cell infiltration and the expression of adhesion molecules on epithelial cells. The results of published studies of the effects of H1-antihistamines on nasal allergic inflammation in humans have been summarized in this chapter. Recent investigations indicate that H1-antihistamines may modulate airway inflammation by downregulating the activity of airway epithelial cells, which have an important role in allergic airway inflammation. The modulation of adhesion molecules and of inflammatory cell infiltration by H1-antihistamines may be beneficial during long-term treatment in patients with allergic rhinitis. The rationale for this hypothesis is the persistence of inflammation on the nasal epithelial cells even when patients are symptom-free (16). All of the events affected by H1-antihistamines are important in the allergic inflammation cascade. The underlying mechanisms for such effects remain unclear, but are unrelated to H1-antagonist activity. Several studies have demonstrated that H1-antihistamines can form an ionic association with cell membranes and inhibit calcium ion influx into the mast cell or basophil plasma membrane, or inhibit Ca2+ release within the cells, and may therefore influence the signal transduction pathways. However, these effects appear to occur at concentrations higher than those achieved in therapeutic practice (126-128). It has recently been hypothesized that the anti-inflammatory activity of H1-antihistamines may be a consequence of their ability to influence the activation of genes responsible for the expression and synthesis of proinflammatory mediators (129). The contribution of the antiallergic effects of H1-receptor antagonists to their clinical efficacy is not fully understood. There have been no data suggesting that H1-antihistamines with well-documented antiallergic properties are superior to the others for which such properties have not been as extensively investigated. Additional studies are needed to elucidate the mechanisms(s) by which H1-antihistamines exert anti-inflammatory effects. This knowledge might lead to the development of novel therapies with more potent and specific anti-inflammatory effects.
来自体外、体内和离体研究的数据表明,第二代抗组胺药具有多种抗过敏、抗炎特性,这些特性似乎与其H1受体阻断活性无关。阿扎他定、氯苯那敏、美吡拉敏和异丙嗪的研究表明,第一代抗组胺药也具有抗过敏、抗炎特性;大多数其他第一代抗组胺药尚未针对这些特性进行研究。体外研究表明,H1抗组胺药可减少肥大细胞和嗜碱性粒细胞促炎介质的释放、炎症细胞(尤其是嗜酸性粒细胞)的趋化作用和活化,以及上皮细胞系中由免疫和非免疫刺激诱导的黏附分子的表达。鼻过敏原激发模型同样证明,H1抗组胺药可抑制肥大细胞和嗜碱性粒细胞释放介质,并减少炎症细胞浸润以及上皮细胞上黏附分子的表达。本章总结了已发表的关于H1抗组胺药对人类鼻过敏性炎症影响的研究结果。最近的研究表明,H1抗组胺药可能通过下调气道上皮细胞的活性来调节气道炎症,而气道上皮细胞在过敏性气道炎症中起重要作用。H1抗组胺药对黏附分子和炎症细胞浸润的调节在变应性鼻炎患者的长期治疗中可能有益。这一假设的理论依据是,即使患者无症状,鼻上皮细胞上的炎症仍会持续存在(16)。H1抗组胺药影响的所有事件在过敏性炎症级联反应中都很重要。此类作用的潜在机制尚不清楚,但与H1拮抗剂活性无关。多项研究表明,H1抗组胺药可与细胞膜形成离子缔合,抑制钙离子流入肥大细胞或嗜碱性粒细胞质膜,或抑制细胞内Ca2+释放,因此可能影响信号转导途径。然而,这些作用似乎发生在高于治疗实践中所达到的浓度时(126 - 128)。最近有人推测,H1抗组胺药的抗炎活性可能是其影响负责促炎介质表达和合成的基因激活能力的结果(129)。H1受体拮抗剂的抗过敏作用对其临床疗效的贡献尚未完全了解。没有数据表明具有充分记录的抗过敏特性的H1抗组胺药比其他尚未广泛研究此类特性的抗组胺药更优越。需要进一步研究以阐明H1抗组胺药发挥抗炎作用的机制。这些知识可能会导致开发出具有更强效和特异性抗炎作用的新疗法。